Answers are grounded in this paper and cite their sources.
Following the first clinical use of autologous CAR-T cell therapy in a patient with relapsed/refractory systemic lupus erythematosus (SLE), numerous clinical trials have been initiated to evaluate the safety and efficacy of CAR-T cell therapy in B cell-mediated autoimmune diseases. 1 , 2 , 3 , 4 , 5 Allogeneic CAR-T cells, distinguished by their homogeneity, rapid availability, and potential for cost effectiveness, represent a promising therapeutic modality for autoimmune diseases. However, the risks of graft-versus-host disease (GVHD), allogeneic rejection, potential genotoxic stress associated with gene editing, and infection risk due to over-immunosuppression limit the broader clinical application of current allogeneic CAR-T cell products. 6 In this study, we demonstrated that an allogeneic CD19-targeted CAR-T cell therapy is effective and safe in treating relapsed/refractory SLE, irrespective of prior neuropsychiatric involvement, using a reduced-intensity lymphodepletion regimen.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: